As previously reported, JonesResearch analyst Catherine Novack upgraded Korro Bio (KRRO) to Buy from Hold with a $23 price target after the company reported Q1 results. While both Korro’s GalNAc-conjugated RNA editor for alpha-1 antitrypsin deficiency and KRRO-121 for urea cycle disorders are likely greater than 12 months from clinical data, the firm likes the upside on the AATD program and notes that some positive readthrough could be seen from a competing base editing program from Wave Life Sciences (WVE). Korro “also has fast-follower advantage” as Wave and Beam Therapeutics (BEAM) define the regulatory path for genetic medicine in AATD.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRRO:
- Korro Bio reports Q1 EPS ($1.69), consensus ($1.98)
- Korro Bio files to sell 7.65M shares of common stock for holders
- Korro Bio price target raised to $22 from $21 at Cantor Fitzgerald
- Korro Bio upgraded to Outperform from Market Perform at Raymond James
- Korro Bio Announces Oversubscribed $85M PIPE Financing